Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days

Outpatient treatments that limit progression to severe coronavirus disease 2019 (COVID-19) are of vital importance to optimise patient outcomes and public health. Monoclonal antibodies (mAb) demonstrated ability to decrease hospitalizations in randomized, clinical trials. However, there are many bar...

Descripción completa

Detalles Bibliográficos
Autores principales: McCreary, Erin K., Bariola, J. Ryan, Minnier, Tami, Wadas, Richard J., Shovel, Judith A., Albin, Debbie, Marroquin, Oscar C., Schmidhofer, Mark, Wisniewski, Mary Kay, Nace, David A., Sullivan, Colleen, Axe, Meredith, Meyers, Russell, Khadem, Tina, Garrard, William, Collins, Kevin, Wells, Alan, Bart, Robert D., Linstrum, Kelsey, Montgomery, Stephanie K., Haidar, Ghady, Snyder, Graham M., McVerry, Bryan J., Seymour, Christopher W., Yealy, Donald M., Huang, David T., Angus, Derek C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654455/
https://www.ncbi.nlm.nih.gov/pubmed/34896293
http://dx.doi.org/10.1016/j.cct.2021.106652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654455/
https://www.ncbi.nlm.nih.gov/pubmed/34896293
http://dx.doi.org/10.1016/j.cct.2021.106652

Ejemplares similares